Extracellular vesicles can modulate numerous processes starting from proliferation and tissue restore, to chemo-resistance and mobile differentiation. With the introduction of tissue and immunological focusing on, extracellular vesicles are additionally more and more seen as promising vectors to ship peptide-based most cancers antigens to the human immune system.
Despite the medical relevance and therapeutic potential of such ‘cell-free’ approaches, the pure antigen presentation landscape exported in extracellular vesicles remains to be largely uncharted, as a result of the difficult nature of such preparations and analyses. In the context of therapeutic vesicle manufacturing, a essential analysis of the similarity in vesicular antigen presentation can also be urgently wanted. In this work, we in contrast the HLA-I peptide ligandomes of extracellular vesicles towards that of whole-cells of the similar cell line.
We discovered that extracellular vesicles not solely over-represent HLA-B complexes and peptide ligands, but additionally cysteinylated peptides that will modulate immune responses. Collectively, these findings describe the pre-existing provision of vesicular HLA complexes which may be utilized to hold peptide vaccines, in addition to the propensity for various peptide and post-translationally modified ligands to be introduced, and will define essential concerns in devising novel EV vaccination methods.
Bioorthogonal protein labelling allows the examine of antigen processing of citrullinated and carbamylated auto-antigens
Proteolysis is key to many organic processes. In the immune system, it underpins the activation of the adaptive immune response: degradation of antigenic materials into quick peptides and presentation thereof on main histocompatibility complexes, results in activation of T-cells. This initiates the adaptive immune response towards many pathogens.
Studying proteolysis is tough, as the oft-used polypeptide reporters are vulnerable to proteolytic sequestration themselves. Here we current a brand new method that permits the imaging of antigen proteolysis all through the processing pathway in an unbiased method. By incorporating bioorthogonal functionalities into the protein in place of methionines, antigens will be adopted throughout degradation, while leaving reactive sidechains open to templated and non-templated post-translational modifications, corresponding to citrullination and carbamylation.
Using this method, we adopted and imaged the post-uptake destiny of the generally used antigen ovalbumin, in addition to the post-translationally citrullinated and/or carbamylated auto-antigen vinculin in rheumatoid arthritis, revealing variations in antigen processing and presentation. Zika virus (ZIKV) has emerged as an vital world well being risk, with the not too long ago acquired capability to trigger extreme neurological signs and to persist inside host tissues.
We beforehand demonstrated that an early Asian lineage ZIKV isolate induces a extremely activated CD8 T cell response particular for an immunodominant epitope in the ZIKV envelope protein in wild-type mice. Here we present {that a} modern ZIKV isolate from the Brazilian outbreak severely limits CD8 T cell immunity in mice and blocks era of the immunodominant CD8 T cell response. This is related to a extra sustained an infection that’s cleared between 7- and 14-days post-infection.
Mechanistically, we show that an infection with the Brazilian ZIKV isolate reduces the cross-presentation capability of dendritic cells and fails to completely activate the immunoproteasome. Thus, our examine supplies an isolate-specific mechanism of host immune evasion by one Brazilian ZIKV isolate, which differs from the early Asian lineage isolate and supplies potential perception into viral persistence related to current ZIKV outbreaks.
Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy considerably will increase the efficiency of anti-PD1 checkpoint remedy
Clinical immunotherapy approaches are missing efficacy in the therapy of glioblastoma (GBM). In this examine, we sought to reverse native and systemic GBM-induced immunosuppression utilizing the Helicobacter pylori neutrophil-activating protein (NAP), a potent TLR2 agonist, as an immunostimulatory transgene expressed in an oncolytic measles virus (MV) platform, retargeted to permit viral entry by means of the urokinase-type plasminogen activator receptor (uPAR).
While single-agent murine anti-PD1 therapy or repeat in situ immunization with MV-s-NAP-uPA offered modest survival profit in MV-resistant syngeneic GBM fashions, the mixture therapy led to synergy with a remedy charge of 80% in mice bearing intracranial GL261 tumors and 72% in mice with CT-2A tumors.
Combination NAP-immunovirotherapy induced huge inflow of lymphoid cells in mouse mind, with CD8+ T cell predominance; therapeutic efficacy was CD8+ T cell dependent. Inhibition of the IFN response pathway utilizing the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the mind and additional potentiated the therapeutic impact of MV-s-NAP-uPA and anti-PD1.
Our findings help the notion that MV strains armed with bacterial immunostimulatory antigens signify an efficient technique to beat the restricted efficacy of immune checkpoint inhibitor-based therapies in GBM, making a promising translational technique for this deadly mind tumor. One case was optimistic for HLA class I and HLA class II antibodies, whereas 9 circumstances have been optimistic for HLA class II antibodies, and the gene loci have been HLA-DR and/or DQ.
Antibody-mediated rejection (AMR) occurred in 4 of 10 sufferers in the DSA-positive group. Liver perform was irregular in 3 of 38 circumstances in the DSA-negative group. Multivariate evaluation revealed that DSA positivity was an impartial danger issue for liver insufficiency and long-term survival of recipients. In addition, Kaplan-Meier survival evaluation demonstrated that there have been vital variations in the survival of graft recipients between the DSA-positive group and the DSA-negative group (P<0.05).
E. coli Antibody |
|||
| abx022977-1ml | Abbexa | 1 ml | 676 EUR |
E. coli antibody |
|||
| 20-ER13 | Fitzgerald | 1 ml | 355 EUR |
|
Description: Rabbit polyclonal E. coli antibody |
|||
E. coli antibody |
|||
| 20C-CR1244GP | Fitzgerald | 1 ml | 468 EUR |
|
Description: Goat polyclonal E. coli antibody |
|||
E. coli antibody |
|||
| 10-E09C | Fitzgerald | 100 ug | 133 EUR |
|
Description: Mouse monoclonal E. coli antibody |
|||
E. coli antibody |
|||
| 10-E10A | Fitzgerald | 500 ug | 493 EUR |
|
Description: Mouse monoclonal E. coli antibody |
|||
E. coli antibody |
|||
| 10-E10B | Fitzgerald | 500 ug | 493 EUR |
|
Description: Mouse monoclonal E. coli antibody |
|||
E. coli antibody |
|||
| 10C-CR1244M1 | Fitzgerald | 100 ug | 408 EUR |
|
Description: Mouse monoclonal E. coli antibody |
|||
Escherichia coli (E. coli) Antibody |
|||
| abx411320-1ml | Abbexa | 1 ml | 509 EUR |
Escherichia coli (E. coli) Antibody |
|||
| abx415692-01mg | Abbexa | 0.1 mg | 634 EUR |
Escherichia coli (E. coli) Antibody |
|||
| abx415712-1ml | Abbexa | 1 ml | 606 EUR |
Escherichia coli (E. coli) Antibody (Biotin) |
|||
| abx411321-1ml | Abbexa | 1 ml | 592 EUR |
Escherichia coli (E. coli) Antibody (FITC) |
|||
| abx411322-1ml | Abbexa | 1 ml | 509 EUR |
Escherichia coli (E. coli) Antibody (Biotin) |
|||
| abx415713-1ml | Abbexa | 1 ml | 718 EUR |
E. coli GroEL Antibody |
|||
| 20012-05011 | AssayPro | 150 ug | 217 EUR |
E. coli CysH Antibody |
|||
| 30281-05111 | AssayPro | 150 ug | 261 EUR |
E. coli DnaJ Antibody |
|||
| 32022-05111 | AssayPro | 150 ug | 261 EUR |
E. coli pykF Antibody |
|||
| 32163-05111 | AssayPro | 150 ug | 261 EUR |
E. coli GOR Antibody |
|||
| 32540-05111 | AssayPro | 150 ug | 261 EUR |
E. coli NDK Antibody |
|||
| 32662-05111 | AssayPro | 150 ug | 261 EUR |
E. coli PPA Antibody |
|||
| 32678-05111 | AssayPro | 150 ug | 261 EUR |
E. coli glk Antibody |
|||
| 32864-05111 | AssayPro | 150 ug | 261 EUR |
E. Coli ldhA Antibody |
|||
| 32898-05111 | AssayPro | 150 ug | 261 EUR |
E. coli deoC Antibody |
|||
| 32936-05111 | AssayPro | 150 ug | 261 EUR |
E. coli Skp Antibody |
|||
| 32971-05111 | AssayPro | 150 ug | 261 EUR |
E. coli nanA Antibody |
|||
| 33092-05111 | AssayPro | 150 ug | 261 EUR |
E. coli O157 Antibody |
|||
| abx024017-1mg | Abbexa | 1 mg | 1010 EUR |
E. coli O157 Antibody |
|||
| abx021684-1mg | Abbexa | 1 mg | 1017 EUR |
E. coli O157 Antibody |
|||
| abx021685-1mg | Abbexa | 1 mg | 996 EUR |
E. coli O157 Antibody |
|||
| abx021686-1mg | Abbexa | 1 mg | 996 EUR |
E. coli O157 Antibody |
|||
| abx021687-1mg | Abbexa | 1 mg | 996 EUR |
E. coli O157 Antibody |
|||
| abx021688-1mg | Abbexa | 1 mg | 940 EUR |
E. coli O157 Antibody |
|||
| abx021689-1mg | Abbexa | 1 mg | 996 EUR |
E. coli Antibody (HRP) |
|||
| abx022972-1ml | Abbexa | 1 ml | 599 EUR |
E. coli Antibody (FITC) |
|||
| abx022974-1ml | Abbexa | 1 ml | 648 EUR |
E. coli Antibody (Biotin) |
|||
| abx022976-1ml | Abbexa | 1 ml | 599 EUR |
E. coli Antibody (HRP) |
|||
| abx022978-1ml | Abbexa | 1 ml | 878 EUR |
E. coli Antibody (Biotin) |
|||
| abx022979-1ml | Abbexa | 1 ml | 739 EUR |
E. coli antibody (FITC) |
|||
| 60-E13 | Fitzgerald | 1 ml | 378 EUR |
|
Description: Rabbit polyclonal E. coli antibody (FITC) conjugated |
|||
E. coli antibody (biotin) |
|||
| 60-E13B | Fitzgerald | 1 ml | 468 EUR |
|
Description: Rabbit polyclonal E. coli antibody (biotin) conjugated |
|||
E. coli antibody (HRP) |
|||
| 60-E14 | Fitzgerald | 1 ml | 408 EUR |
|
Description: Rabbit polyclonal E. coli antibody (HRP) conjugated |
|||
E. coli O157 antibody |
|||
| 10-1490 | Fitzgerald | 100 ug | 136 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli O157 antibody |
|||
| 10-1521 | Fitzgerald | 100 ug | 142 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli O157 antibody |
|||
| 10-E12A | Fitzgerald | 100 ug | 385 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. coli O157 antibody |
|||
| 10C-CR1295M3 | Fitzgerald | 100 ug | 392 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody |
|||
E. Coli HCP antibody |
|||
| 20R-EG001 | Fitzgerald | 1 ml | 837 EUR |
|
Description: Goat polyclonal E. Coli HCP antibody |
|||
E. coli GroL |
|||
| DAG1704 | Creative Diagnostics | 100 ug | 915 EUR |
E. coli GroS |
|||
| DAG1705 | Creative Diagnostics | 100 ug | 915 EUR |
E. coli DsbA |
|||
| DAG1712 | Creative Diagnostics | 100 ug | 915 EUR |
E. coli GrpE |
|||
| DAG1714 | Creative Diagnostics | 100 ug | 1027 EUR |
E. coli Glycerol Kinase Antibody |
|||
| 32699-05111 | AssayPro | 150 ug | 261 EUR |
E. coli Tryptophanase (Tnase) Antibody |
|||
| 33517-05111 | AssayPro | 150 ug | 261 EUR |
Mouse antibody for E. coli |
|||
| 1063 | Virostat | 100 ug | 365.38 EUR |
|
Description: This is Mouse monoclonal FITC conjugated antibody against E coli O157 for WB, ELISA. |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC040207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC040207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405S conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC470207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC470207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF647 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC550207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC550207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF555 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCB0207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCB0207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Biotin conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC810207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC810207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680R conjugate, Concentration: 0.1mg/mL |
|||
E. coli Enterotoxin B Antibody |
|||
| abx021678-1mg | Abbexa | 1 mg | 599 EUR |
E. coli Enterotoxin B Antibody |
|||
| abx021679-1mg | Abbexa | 1 mg | 606 EUR |
E. coli Enterotoxin B Antibody |
|||
| abx021680-1mg | Abbexa | 1 mg | 599 EUR |
E. coli O157 Antibody (FITC) |
|||
| abx021683-1mg | Abbexa | 1 mg | 2332 EUR |
E. coli O157:H7 Antibody |
|||
| abx022980-1mg | Abbexa | 1 mg | 599 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023834-1mg | Abbexa | 1 mg | 732 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023835-1mg | Abbexa | 1 mg | 732 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023836-1mg | Abbexa | 1 mg | 732 EUR |
E. coli Enterotoxin LT Antibody |
|||
| abx023837-1mg | Abbexa | 1 mg | 732 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023838-1mg | Abbexa | 1 mg | 878 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023839-1mg | Abbexa | 1 mg | 878 EUR |
E. coli Enterotoxin STp Antibody |
|||
| abx023840-1mg | Abbexa | 1 mg | 878 EUR |
E. coli O157 (9.88) Antibody |
|||
| BNC700207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC700207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF770 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC880207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC880207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF488A conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC940207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC940207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF594 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC680207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC680207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF568 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCA0207-250 | Biotium | 250uL | 383 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),APC conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCAP0207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCAP0207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUM0207-50 | Biotium | 50uL | 395 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), 1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCP0207-250 | Biotium | 250uL | 383 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),PerCP conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC050207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC050207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF405M conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC400207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC400207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF640R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCR0207-250 | Biotium | 250uL | 383 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),RPE conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUB0207-100 | Biotium | 100uL | 209 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNUB0207-500 | Biotium | 500uL | 458 EUR |
|
Description: Primary antibody against E. coli O157 (9.88), Concentration: 0.2mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC430207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC430207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF543 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCH0207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNCH0207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC610207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC610207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF660R conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC800207-100 | Biotium | 100uL | 199 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 (9.88) Antibody |
|||
| BNC800207-500 | Biotium | 500uL | 544 EUR |
|
Description: Primary antibody against E. coli O157 (9.88),CF680 conjugate, Concentration: 0.1mg/mL |
|||
E. coli O157 antibody (FITC) |
|||
| 61C-CR1295M1F | Fitzgerald | 100 ug | 408 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody (FITC) |
|||
E. coli O157 antibody (FITC) |
|||
| 61C-CR1295M4F | Fitzgerald | 100 ug | 468 EUR |
|
Description: Mouse monoclonal E. coli O157 antibody (FITC) |
|||
E. coli O157:H7 antibody |
|||
| 70-XG13 | Fitzgerald | 1 mg | 612 EUR |
|
Description: Affinity purified Goat polyclonal E. coli O157:H7 antibody. |
|||
E. coli antibody (K99 Pilus) |
|||
| 10-E20A | Fitzgerald | 500 ug | 493 EUR |
|
Description: Mouse monoclonal E. coli antibody (K99 Pilus) |
|||
Leukemia - ALL Exosome |
|||
| P141-ALL | 101Bio | - | Ask for price |
Escherichia coli Serotype O2 (E. coli O2) Antibody |
|||
| abx411330-02mg | Abbexa | 0.2 mg | 565 EUR |
Escherichia coli Serotype O15 (E. coli O15) Antibody |
|||
| abx411331-02mg | Abbexa | 0.2 mg | 565 EUR |
Escherichia coli Serotype O20 (E. coli O20) Antibody |
|||
| abx411332-02mg | Abbexa | 0.2 mg | 565 EUR |
Leukemia - ALL Exosome RNA |
|||
| P241-ALL | 101Bio | - | Ask for price |
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0123 | Creative Diagnostics | 1 ml | 833 EUR |
Rabbit Anti-E. coli all ag's Polyclonal Antibody |
|||
| DPAB0126 | Creative Diagnostics | 1 ml | 955 EUR |
E. coli FimC [His] |
|||
| DAG1666 | Creative Diagnostics | 100 ug | 1027 EUR |
E. coli Eco [His] |
|||
| DAG1667 | Creative Diagnostics | 50 ug | 1027 EUR |
E. coli RecA Protein |
|||
| 01-001 | Sceti | 200 ug | 205 EUR |
|
Description: The E. coli RecA Protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli LexA repressor |
|||
| 01-005 | Sceti | 50 ug | 479 EUR |
|
Description: The E. coli LexA repressor is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli LexA repressor |
|||
| 01-006 | Sceti | 250 ug | 1184 EUR |
|
Description: The E. coli LexA repressor is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvA protein |
|||
| 01-007 | Sceti | 50 ug | 479 EUR |
|
Description: The E. coli RuvA protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvA protein |
|||
| 01-008 | Sceti | 250 ug | 1184 EUR |
|
Description: The E. coli RuvA protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvB protein |
|||
| 01-009 | Sceti | 50 ug | 479 EUR |
|
Description: The E. coli RuvB protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvB protein |
|||
| 01-010 | Sceti | 250 ug | 1184 EUR |
|
Description: The E. coli RuvB protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvC protein |
|||
| 01-011 | Sceti | 50 ug | 479 EUR |
|
Description: The E. coli RuvC protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli RuvC protein |
|||
| 01-012 | Sceti | 250 ug | 1184 EUR |
|
Description: The E. coli RuvC protein is available in Europe and for worldwide shipping via Gentaur. |
|||
E. coli O 157 |
|||
| abx291002-100mg | Abbexa | 100 mg | 620 EUR |
E. coli Topoisomerase IV |
|||
| TG2000EC-1 | TopoGen | 250 units | 448 EUR |
E. coli Topoisomerase IV |
|||
| TG2000EC-3 | TopoGen | 500 units | 683 EUR |
E. coli Topoisomerase IV |
|||
| TG2000EC-5 | TopoGen | 1000 units | 1052 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-1 | TopoGen | 100 units | 324 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-3 | TopoGen | 500 units | 705 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-5 | TopoGen | 1000 units | 1164 EUR |
E. coli DNA Gyrase |
|||
| TG2000G-7 | TopoGen | 2000 units | 1836 EUR |
Enterotoxin STp (E. coli) |
|||
| H-6248.0500 | Bachem | 0.5mg | 696 EUR |
|
Description: Sum Formula: C81H110N20O26S6; CAS# [115474-04-9] net |
|||
Enterotoxin STp (E. coli) |
|||
| H-6248.1000 | Bachem | 1.0mg | 1180 EUR |
|
Description: Sum Formula: C81H110N20O26S6; CAS# [115474-04-9] net |
|||
E. coli DNA Ligase |
|||
| M1217-100 | Biovision | 321 EUR | |
E. coli Exonuclease I |
|||
| M1222-100 | Biovision | 251 EUR | |
E. coli Exonuclease III |
|||
| M1223-100 | Biovision | 267 EUR | |
RecA Protein E. coli |
|||
| M1231-200 | Biovision | 202 EUR | |
E. coli Recombinant IDNK |
|||
| P1050-10 | Biovision | 164 EUR | |
E. coli Recombinant IDNK |
|||
| P1050-50 | Biovision | 381 EUR | |
Recombinant E. coli, Glucokinase |
|||
| P1054-10 | Biovision | 164 EUR | |
Recombinant E. coli, Glucokinase |
|||
| P1054-50 | Biovision | 381 EUR | |
E. Coli Recombinant TRXB |
|||
| 6331-100 | Biovision | 425 EUR | |
E. Coli Recombinant SlyD |
|||
| 6366-100 | Biovision | 457 EUR | |
Benzonase, E. Coli Recombinant |
|||
| 7680-25 | Biovision | 332 EUR | |
Benzonase, E. Coli Recombinant |
|||
| 7680-5 | Biovision | 137 EUR | |
TesA, E. coli esterase |
|||
| 0306-1 | AthenaES | 100 Units | 421 EUR |
TesA, E. coli esterase |
|||
| 0306-5 | AthenaES | 500 Units | 1705 EUR |
Human Escherichia coli (E. coli) ELISA Kit |
|||
| abx052493-96tests | Abbexa | 96 tests | 668 EUR |
Cow Escherichia coli (E. coli) ELISA Kit |
|||
| abx055785-96tests | Abbexa | 96 tests | 668 EUR |
The positivity of DSAs after pediatric liver transplantation was intently associated to the incidence of AMR. These outcomes prompt that DSAs needs to be routinely monitored post-operatively, and that DSA-positive recipients needs to be screened as quickly as attainable and given acceptable therapy.